Clinical Trial Design: Statistical Options/Challenges Panel Discussion

First International Summit on Interventional Pharmacoeconomics

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Varsha Gandhi, PhD, on Ibrutinib

Welcome and Introduction to Vi3C

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Mar

Today In Oncology

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Varsha Gandhi, PhD, on Ibrutinib

Welcome and Introduction to Vi3C

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Benmelstobart Plus Anlotinib in First-Line Treatment for PD-L1–Positive Advanced NSCLC

Optical Genome Mapping Detects Additional Genetic Variants in Nearly 20% of Individuals With Acute Leukemia

New Prostate Cancer Risk Classification With PSMA-PET

FDA Consolidates Systems Into One Cohesive Adverse Event Monitoring Tool

No Recurrence-Free Survival Benefit With Adjuvant Pembrolizumab in Hepatocellular Carcinoma